Boston Scientific today shared new clinical data supporting multiple therapies at the Heart Rhythm Society (HRS) 2025 Meeting ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

Boston Scientific has proven itself to ... in atrial fibrillation and further growth of the Watchman left atrial appendage closure device, slightly offset by more gradual margin gains pressured ...

Boston Scientific will face more benign competition than previously feared when it comes to pulsed field ablation, according ...

Shares of the medical device maker soared nearly 10 per cent in premarket trading, as the raised forecast alleviated investor ...

Growth in the first quarter for Boston Scientific Corp.’s blockbuster products, Farapulse and Watchman, pushed the company well over analysts’ expectations and gave management confidence to raise its ...

April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation ... PFA System and subsequent implant of the WATCHMAN™ Left Atrial Appendage Closure Device in a concomitant procedure.